Issue link: http://www.e-digitaleditions.com/i/830814
Inhalation JUNE2017 27 federal agencies, to oversee develop- ment of the Addendum Guidelines to specifically address the prevention of peanut allergy. The committee's expert panel of specialists from clini- cal, scientific and public health areas used a literature review of food allergy prevention research and their own expert opinions to prepare the draft guidelines. Improving lives, reducing healthcare costs "Preventing the development of peanut allergy will improve and save lives and lower healthcare costs," said NIAID Director Anthony S. Fauci, MD. "We expect that wide- spread implementation of these guidelines by healthcare providers will prevent the development of peanut allergy in many susceptible children and ultimately reduce the prevalence of peanut allergy in the United States." ADVERTISER INDEX A Astech 7 C Capsugel 1 Catalent Pharma Solutions 5 Copley Scientific 3 H Hovione 17 M Meggle Group Cover 2 MSP Cover 4 P Proveris Scientific 13 R RDD Europe 15 Recipharm 8 S Siemens 11 BACKPAGE continued from page 28 RESPIRATORY ANDCOMPENDIAL NEWS NIH designates $42.7 million for food allergy research consortium BETHESDA, MD—Funding News reports that the United States National Institutes of Health (NIH) plans to award $42.7 million over seven years to the Consortium of Food Allergy Research (CoFAR) to continue evalu- ating new approaches to treat food allergy. Established in 2005, the CoFAR has been continuously funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH. The first year of funding has been awarded. In subsequent years, awards will be based on the availability of funds. Research is being conducted at seven universities and medical cen- ters. CoFAR scientists are working to develop immunotherapy approaches to treat food allergy. To date, they have demonstrated the clinical benefit of egg oral immunotherapy and identi- fied the most promising routes, doses and durations of egg and peanut immunotherapy for further study. In addition, they have identified genes associated with an increased risk for peanut allergy among Americans of European descent. An estimated 4 per- cent of adults and 5 percent of children in the United States have food allergy. The prevalence of food allergy is rising without a known cause and no treat- ment for food allergy has yet been approved by the US Food and Drug Administration (FDA). EMA to pursue closer interaction with academia LONDON, UK—The European Medicines Agency (EMA) reports that it has adopted a framework and action plan to formalize, structure and further References The article is based on content from the NIH news release "NIH-Spon- sored Expert Panel Issues Clinical Guidelines to Prevent Peanut Allergy," January 5, 2017 and "Peanut Allergy: Early Exposure Is Key to Prevention," The NIH Director's Blog, posted January 10, 2017 by Dr. Francis Collins. 1. Guidelines for the Diagnosis and Management of Food Allergy in the U n i t e d S t a t e s : R e p o r t o f t h e NIAID-Sponsored Expert Panel. NIAID-Sponsored Expert Panel, Boyce JA, et al, J Allergy Clin Immunol 2010 Dec; 126 (6 Suppl): S1-58. 2. Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy. The LEAP Study Team, N Engl J Med 2015 Feb 23. 3. Effect of Avoidance on Peanut Allergy After Early Peanut Con- sumption. Immune Tolerance Net- work LEAP-On Study Team, N Engl J Med 2016 Apr 14; 374(15): 1435-1443. develop interactions with the academic community in the context of the Euro- pean medicines regulatory network. "The framework will allow us to inte- grate cutting-edge scientific knowl- edge more tightly into our activities. It will also help academic start-ups bene- fit from advice from the EU regulatory network to translate their discoveries into patient-focused medicines," said EMA's Executive Director Guido Rasi. The action plan includes initia- tives for mutual education and train- ing, staff exchange programs to pro- mote mutual learning, a strategic research agenda for regulatory science and the creation of an EMA entry point for academia to receive informa- tion on available support within the EU Regulatory Network.